Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.69 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30548176 | 1.00 | ESR2 (0.69) | ESR2NR1H2DRD2MAPK1GPR119 | |
| SCHEMBL2416879 | 0.95 | NR1H2 (0.67) | ESR2NR1H2DRD2MAPK1GPR119 | |
| SCHEMBL29586616 | 0.95 | NR1H2 (0.67) | ESR2NR1H2DRD2MAPK1GPR119 | |
| SCHEMBL2995065 | 0.93 | ESR2 (0.59) | ESR2NR1H2DRD2MAPK1GPR119 | |
| SCHEMBL2123156 | 0.92 | ESR2 (0.57) | ESR2NR1H2DRD2GPR119MAPT | |
| SCHEMBL566550 | 0.90 | ESR2 (0.53) | ESR2NR1H2DRD2MAPK1GPR119 | |
| SCHEMBL3695530 | 0.89 | ESR2 (0.61) | ESR2NR1H2DRD2MAPK1GPR119 | |
| SCHEMBL24265587 | 0.88 | NR1H2 (0.58) | ESR2NR1H2DRD2MAPK1GPR119 | |
| SCHEMBL30548188 | 0.88 | NR1H2 (0.58) | ESR2NR1H2DRD2MAPK1GPR119 | |
| SCHEMBL3009208 | 0.88 | ESR2 (0.69) | ESR2NR1H2MAPK1NAMPTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116507326-A | Compounds as GLP-1R agonists | 拓臻制药公司 | 2023-07-28 | — | — | CN | disclosed |
| US-11110091-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20190321366-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10172860-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180085370-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| WO-2017222950-A1 | 3-HETEROCYCLYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | WO | disclosed |
| EP-3210982-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | Gilead Sciences, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170065592-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. | 2017-03-09 | — | — | US | disclosed |
| EP-2818469-B1 | Intermediates for the preparation of modulators of toll-like receptors | GILEAD SCIENCES INC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-9452166-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-8039674-B2 | Amino-substituted cyclic compound for EDG-1(endothelial differentiation gene) and/or EDG-6-mediated diseases; transplant rejection, autoimmune diseases, allergies, asthma, multiple organ failure, ischemia, reperfusion injury, lung or liver fibrosis; antitumor agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| WO-2010146105-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010077613-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1760071-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
| WO-1995014469-A1 | NOVEL SPIROCYCLES | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| US-5403846-A | Antiarrhythmic agents | MERCK & CO., INC. (US) | 1995-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085370-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | ESR2 259/4885NR1H2 45/4885DRD2 3003/4885 |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | ESR2 259/4885NR1H2 45/4885DRD2 3003/4885 |
| US-10172860-B2 | Modulators of toll-like receptors | TLR3, TLR2, TLR6 | ESR2 259/4885NR1H2 45/4885DRD2 3003/4885 |
| US-11110091-B2 | Modulators of toll-like receptors | TLR3, TLR2, TLR6 | ESR2 259/4885NR1H2 45/4885DRD2 3003/4885 |
| US-20190321366-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | ESR2 259/4885NR1H2 45/4885DRD2 3003/4885 |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | S1PR1, EDNRA, S1PR3 | ESR2 376/4885NR1H2 122/4885DRD2 597/4885 |
| US-20170065592-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | ESR2 259/4885NR1H2 45/4885DRD2 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.